Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Reneo Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RPHM
)
1.820
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Reneo Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
Next >
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
October 04, 2024
From
Reneo Pharmaceuticals, Inc.; OnKure Therapeutics, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
October 02, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
September 03, 2024
From
Halper Sadeh LLC
Via
Business Wire
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
August 29, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SBOW, AGR, RPHM on Behalf of Shareholders
June 25, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM)
June 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
June 21, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBOW, PRFT, RPHM on Behalf of Shareholders
June 18, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM), Perficient, Inc. (Nasdaq - PRFT)
June 18, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BATL, DRQ, RPHM, PRFT on Behalf of Shareholders
June 14, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM), Perficient, Inc. (Nasdaq - PRFT)
June 07, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE – AGR), SilverBow Resources, Inc. (NYSE – SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq – RPHM), Perficient, Inc. (Nasdaq – PRFT)
May 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
ALERT: Halper Sadeh LLC Continues to Investigate PRFT, SBOW, RPHM, UNIT; Shareholders are Encouraged to Contact the Firm
May 29, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM), Perficient, Inc. (Nasdaq - PRFT)
May 20, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
May 14, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reneo Pharmaceuticals, Inc. (Nasdaq – RPHM), ALLETE, Inc. (NYSE – ALE), Perficient, Inc. (Nasdaq – PRFT), Hibbett, Inc. (Nasdaq – HIBB)
May 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
May 13, 2024
From
Halper Sadeh LLC
Via
Business Wire
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024
From
Reneo Pharmaceuticals, Inc.; OnKure, Inc
Via
GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
March 28, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
December 14, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 13, 2023
Topline data results from the pivotal STRIDE study are expected in December 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
November 02, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
October 09, 2023
Topline data results from the STRIDE study are expected in December 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
October 06, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
